1 2

The Post-Septic Peripheral Myeloid Compartment Reveals Unexpected Diversity in Myeloid-Derived Suppressor Cells

2

Evan L. Barrios¹[†], John Leary²[†], Dijoia B. Darden¹, Jaimar C. Rincon¹, Micah Willis¹,
Valerie E. Polcz¹, Gwendolyn S. Gillies¹, Jennifer A. Munley¹, Marvin L. Dirain¹, Ricardo
Ungaro¹, Dina C. Nacionales¹, Marie-Pierre L. Gauthier³, Shawn D. Larson¹, Laurence

7 Morel⁴, Tyler J. Loftus¹, Alicia M. Mohr¹, Robert Maile¹, Michael P. Kladde³, Clayton E.

- 8 Mathews⁵, Maigan A. Brusko⁵, Todd M. Brusko⁵, Lyle L. Moldawer¹, Rhonda Bacher^{2*},
- 9 **Philip A. Efron**¹
- 10
- ¹Sepsis and Critical Illness Research Center, Department of Surgery, University of Florida
 College of Medicine; Gainesville, Florida, USA
- ¹³²Department of Biostatistics, University of Florida College of Medicine and Public Health and
- 14 Health Sciences, Gainesville, Florida, USA
- ¹⁵ ³Department of Biochemistry and Molecular Biology, University of Florida College of Medicine,
- 16 Gainesville, Florida, USA
- ⁴Department of Microbiology and Immunology, University of Texas San Antonio School of
- 18 Medicine; San Antonio, Texas, USA
- ⁵Department of Pathology, Immunology and Laboratory Medicine, University of Florida College
- 20 of Medicine; Gainesville, Florida, USA
- 21

22 Footnotes:

- ²³ †These authors contributed equally to the work and share first authorship.
- ²⁴ *These authors are both corresponding authors.
- 25

26 ***Correspondence:**

- 27 Philip A. Efron, M.D.
- 28 Department of Surgery, University of Florida College of Medicine
- 29 Room 6116, Shands Hospital
- 30 1600 SW Archer Road
- 31 Gainesville, Florida 32610-0019
- 32 ORCID: 0000-0002-3931-650X
- 33 Phone: 352-265-0494
- 34 FAX: 352-265-0676
- 35 Email: <u>philip.efron@surgery.ufl.edu</u>
- 36
- 37 Rhonda Bacher, Ph.D.
- 38 Department of Biostatistics, University of Florida
- 39 Gainesville, Florida 32610-0019
- 40 Email: <u>rbacher@ufl.edu</u>
- 41
- 42 Keywords: myeloid-derived suppressor cells, sepsis, transcriptomics, single-cell RNA
- 43 sequencing, chronic critical illness
- 44
- 45 Word count: 6869
- 46 **Figure and Table Count:** 14

47 Abstract

48

49 Sepsis engenders distinct host immunologic changes that include the expansion of myeloid-50 derived suppressor cells (MDSCs). These cells play a physiologic role in tempering acute inflammatory responses but can persist in patients who develop chronic critical illness. The 51 origins and lineage of these MDSC subpopulations were previously assumed to be discrete and 52 unidirectional; however, these cells exhibit a dynamic phenotype with considerable plasticity. 53 Using Cellular Indexing of Transcriptomes and Epitopes by Sequencing followed by 54 transcriptomic analysis, we identify a unique lineage and differentiation pathway for MDSCs 55 56 after sepsis and describe a novel MDSC subpopulation. Additionally, we report that the heterogeneous response of the myeloid compartment of blood to sepsis is dependent on clinical 57 outcome. 58

1 Introduction 60

61

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host 62 response to infection (1), with survivors experiencing either a rapid recovery or chronic critical 63 illness (CCI) (2). The emergency myelopoietic response to sepsis is characterized by 64 65 hematopoietic stem and progenitor cell (HSPC) expansion and preferential differentiation along myeloid pathways (3-7). We and others have previously demonstrated that sepsis induces an 66 expansion of circulating myeloid-derived suppressor cells (MDSCs), and that both an increase in 67 and persistence of specific MDSC subpopulations are seen in sepsis patients with poor clinical 68 outcomes (4, 8, 9). 69

Three MDSC subpopulations are typically described based on cell surface expression, 70 mechanisms of immune suppression, and inflammatory profiles: granulocytic (PMN-), 71 monocytic (M-), and early (E-) MDSCs (10, 11). Although these MDSCs differ phenotypically, 72 they are all capable of suppressing T-lymphocyte proliferation (4, 12). As research into the 73 myeloid compartment during inflammation expands, the complexity of intermediate cell types is 74 just beginning to be understood. Indeed, Hegde et al. recently concluded that suppressive 75 myeloid cell types, including MDSCs, "are highly heterogeneous and context dependent" (13). 76 77 The authors presented an emergent view of MDSCs that emphasizes heterogeneity and plasticity in contrast to the classical view of MDSCs as the midpoint in a differentiation pathway that 78 79 results in terminally-differentiated monocytes and granulocytes (13).

80 Single-cell RNA-sequencing (scRNA-seq) details the transcriptomes of complex and heterogeneous cell mixtures. An extension of this technique, Cellular Indexing of 81 Transcriptomes and Epitopes by Sequencing (CITE-seq), simultaneously profiles cell surface 82 proteins for each cell. We initially performed CITE-seq in order to identify MDSC 83 subpopulations based on cell surface makers/cell phenotypes, as our previous results (14) 84 indicated that MDSCs from septic patients may not express some of the classic genes found in 85 MDSCs from cancer patients, making them difficult to identify. We compared the transcriptomes 86 of myeloid cells from healthy subjects, acutely septic patients, and patients with good and poor 87 clinical outcomes at later time points after sepsis. We found that MDSC subpopulations evolve 88 over time and that outcome-dependent MDSC subpopulations exist. Specifically, we identified a 89 novel hybrid (H)-MDSC phenotype unique to some sepsis survivors with poor clinical outcomes 90 as well as acutely septic patients that progressed to CCI. Additionally, our findings suggest that 91 92 the proliferation and cytokine production of lymphocytes, when co-cultured with MDSCs, vary at different time points after sepsis. Importantly, MDSCs do not express key genes seen in cancer 93 whose downstream products suppress T-cell responsiveness. Overall, our results demonstrate a 94 critical need for disease- or "context-" specific understanding of MDSCs when considering host-95 specific immune dysfunction and potential therapies. 96

97 98

2 **Materials and Methods**

99

2.1 100 **Study Design** 101

Our study design was previously reported by Darden, et al (14). To summarize, this 102 prospective, observational cohort study was registered with *clinicaltrials.gov* (NCT02276417) 103 and conducted at a tertiary care, academic research hospital. The objective of the study was to 104 105 better understand the myeloid response (specifically blood MDSCs) to acute sepsis, and to identify transcriptomic differences in sepsis patients who rapidly recover versus those who 106

develop CCI. Our hypothesis was that differences in the myeloid transcriptomic landscape could 107 108 explain why some sepsis patients rapidly recover while others develop CCI.

Sepsis designation occurred through an electronic medical record-based Modified Early 109 Warning Signs-Sepsis Recognition System (MEWS-SRS), which uses white blood cell count, 110 heart rate, respiration rate, blood pressure, and mental status to identify patients at-risk for sepsis. 111 All patients with sepsis were treated with early goal-directed fluid administration, initiation of 112 broad-spectrum antibiotics, and vasopressor administration if appropriate. Antibiotic treatment 113 was tailored to culture results and antibiotic resistance information. 114 Inclusion criteria: 115 Admission to the intensive care unit (ICU) 116 117 Age >17 years Diagnosis of sepsis or septic shock according to the 2016 SCM/ESICM 118 International Sepsis Definitions Conference (1) 119 Initial septic episode while hospitalized 120 Management of patient via the sepsis clinical management protocol (15) 121 Exclusion criteria: 122 123 Refractory shock Inability to achieve source control 124 Pre-sepsis expected lifespan <3 months 125 Expected withdrawal of care 126 Severe congestive heart failure (NYHA Class IV) 127 Child-Pugh Class C liver disease or undergoing evaluation for liver 128 transplant 129 HIV infection with CD4⁺ count <200 cells/mm³ 130 Prior organ transplant, use of chronic steroids, or immunosuppressive 131 agents 132 Pregnancy 133 Institutionalized or other vulnerable patients 134 Chemotherapy or radiotherapy treatment within 30 days of sepsis onset 135 Severe traumatic brain injury (defined by radiologic evidence and GCS <8) 136 Spinal cord injury with permanent deficits 137 Unable to obtain informed consent 138 CCI was defined as ICU length of stay >13 days with persistent organ dysfunction as 139 measured by the Sequential Organ Failure Assessment (SOFA) Score. Patients were also 140

designated CCI with <14 days ICU length of stay if they were transferred to another hospital, or 141 discharged to a long-term acute care facility or hospice with evidence of persistent organ 142 dysfunction (4, 16). Patients were excluded from analysis if they died within 14 days of onset of 143 sepsis (4, 16). 144

- 145
- 2.2 146
- 147

Human blood collection and sample preparation

Whole blood samples were collected at the following time points: 4 ± 1 days and 14-21 148 days after sepsis (16). For the former, we enrolled four patients diagnosed with septic shock (1) 149 in order to guarantee a strong host response and transcriptomic alterations in circulating 150 151 leukocytes. Interestingly, only half of these septic shock patients went on to develop CCI; the mortality for this cohort was 50% (17, 18). Samples from five patients who developed CCI and 152

four patients who rapidly recovered after sepsis were obtained from additional patients between 153 days 14-21 after sepsis diagnosis. We previously determined this time point to be key to MDSC 154 differentiation as well as distinguishing CCI from rapid recovery (4, 16). In 155 addition. whole 156 blood was collected from 12 healthy subjects (1, 2). The proportion of men and women did not differ between sepsis patients and healthy subjects. Healthy subjects trended towards being 157 younger than sepsis patients, although they still met the criteria of middle age (>45 years), 158 encompassing patients who have poor outcomes after sepsis compared to younger cohorts (17, 159 18). Healthy subjects and septic patients had similar comorbidity scores, and similar underlying 160 comorbidities (most commonly hypertension, chronic obstructive pulmonary disease, and 161 diabetes mellitus). 162

Each blood collection underwent two enrichment procedures. PBMCs were collected from half of each sample using Ficoll-PaqueTM PLUS (Millipore Sigma, St. Louis, MO) and density gradient centrifugation. Myeloid cells were collected using RosetteSepTM HLA Myeloid Cell Enrichment Kit (STEMCELL Technologies, Vancouver). A 1:3 mixture of enriched PBMCs: myeloid cells was created in order to adequately analyze the small target population (MDSCs, especially in control subjects) while also allowing for characterization of other important immune cell populations using CITE-seq.

170 171

172

2.2.1 Human T-cell isolation and proliferation assay

Total T cells in the PBMC suspension were captured by immunomagnetic negative 173 selection using EasySepTM Human T Cell Isolation Kit (STEMCELL Technologies, Vancouver) 174 according to the manufacturer's instructions. Isolated CD3⁺ lymphocytes were labeled with cell 175 trace violet (Thermo Fisher, Waltham, MA) to assess T-cell proliferation. T lymphocytes (1 x 176 10^5 CD3⁺) were seeded into a 96-well plate and stimulated with soluble anti-CD3/CD28 177 antibodies (STEMCELL Technologies, Vancouver) or without, which served as the control. 178 CD66b⁺ cells were also isolated from the PBMC fractions using EasySepTM positive selection kit 179 (STEMCELL Technologies, Vancouver) and were co-cultured with stimulated T cells in a 1:1 180 ratio at 37°C and 5% CO₂. After 4 days, cells were harvested and supernatants were obtained for 181 cytokine analysis. Cells were stained with anti-CD8 FITC and anti-CD4 PE and analyzed via 182 flow cytometry (ZE5 Cell Analyzer, Bio-Rad Laboratories, CA). Proliferation indices were 183 184 calculated as the total number of cell divisions divided by the number of cells that went into division (considering cells that underwent at least one division). 185

186

187 2.2.2 Cytokine analysis

188

Human high sensitivity T cell magnetic bead 6-plex panels (IFN- γ , IL-10, IL-12 (p70), IL-17α, IL-2, IL-23) were purchased from EMD Millipore (Billerica, MA). Supernatants after cell culture were used for T cell-associated cytokines. The xPONENT software (EMD Millipore, Billerica, MA) was used for cytokine analysis.

193

195

194 **2.2.3 Flow cytometry**

PBMC samples were analyzed fresh (not frozen and rethawed) due to differential viability of cell populations, particularly granulocytes.(19, 20) Although the PBMC fraction excludes mature granulocytes, it does contain low-density granulocytes that are presumed to

include PMN-MDSCs (21). Classically, human blood MDSCs are defined from PBMCs as: M-199 (CD11b⁺CD14⁺CD33⁺HLA⁻DR^{low/-}) and 200 **MDSCs** PMN-MDSCs (CD11b⁺CD15⁺HLA⁻ DR^{low}CD66b⁺) (22). Our preliminary flow cytometric analysis revealed that CD15 was not a 201 202 good cell surface marker to isolate CD14⁻ cells from PBMCs (Fig. S1C). In fact, the analysis of CD33⁺CD11b⁺HLA⁻DR^{low/-} cells revealed heterogeneity in CD14 and CD15 cell surface 203 expression. Thus, we chose to isolate CD66b⁺ cells from PBMCs to obtain PMN-MDSCs (Fig. 204 **S1C**). 205

- 206
- 2.3 **Statistics** 207
- 208

209 2.3.1 scRNA-seq read preprocessing 210

Gene expression and feature-barcoding data were generated using 10x Genomics v1.1 5' 211 chemistry and were sequenced on an Illumina HiSeq® with a target of 10,000 cells per sample 212 (23). The **Cell Ranger** (10X Genomics) software suite was used to process base calls into 213 FASTQ files, which were checked for quality control aberrations using FastQC v0.11.7 (24). A 214 215 spliced + intronic, or *6plice*, reference transcriptome was generated from the hg38 reference genome (25). Reads were pseudoaligned to the reference transcriptome with alevin-fry v 0.8.1; 216 USA mode was used for gene expression reads in order to provide separate quantifications of 217 218 spliced, unspliced, and ambiguous mRNA abundance (26-28). The counts of 11 cell surface proteins of interest were also quantified using alevin-fry. Splicing-aware gene expression 219 quantification was performed using Ensembl transcript IDs, with final counts matrices 220 aggregated using Ensembl gene IDs. 221

- 222 223
- 224

2.3.2 scRNA-seq data processing

Downstream data processing and analysis were performed primarily in R v4.2.3, with 225 some additional processes written in Python v3.8 as required (29, 30). After loading the 226 227 unfiltered spliced, unspliced, and ambiguous mRNA counts into R using fishpond package v2.4.1, we defined total mRNA counts as the elementwise sum of all three counts matrices and 228 added the ambiguous counts to the spliced counts matrix (31). Unless otherwise specified, total 229 230 mRNA counts were used as input throughout the analysis. Empty droplets and ambient mRNA were then identified and filtered out using the DropletUtils package v1.18.1 (32, 33). Cells with 231 an estimated false discovery rate of <0.01 were kept for each sample. Next, the percentage of 232 spliced reads coming from mitochondrial genes was computed for each cell, and cells with less 233 than 5% mitochondrial DNA were kept (no significant difference between healthy and septic 234 samples). Cell surface protein counts were imported as well, and cells that had valid gene 235 expression barcodes but not protein barcodes were assigned a value of "0" for each protein. The 236 raw counts matrices were then formatted and merged using the Seurat package v4.3.0, providing 237 a single object with total, unspliced, and spliced mRNA as well as cell surface protein assays 238 (34). Cells with less than three spliced and unspliced transcripts were removed by filtering; thus, 239 the final merged dataset comprised 28,952 genes and 119,062 cells. 240

The total mRNA counts were scaled by library size factors and log1p-normalized, while 241 protein counts were normalized via a centered log ratio transformation across each gene. Four 242 243 thousand highly variable genes (HVGs) were identified using a local polynomial regression between the log of expression variance and the log of mean expression as implemented in the 244

FindVariableFeatures function. After scaling the normalized counts, 100 principal components 245 were computed using the set of HVGs as input, and each cell was scored and assigned a cell 246 cycle phase as described previously (35). Next, the 25 different samples were integrated by the 247 248 **Harmony** package v0.1.1, which corrects the existing Principal Component Analysis (PCA) embedding (36). The first 50 principle components were used as input, and a two-dimensional 249 UMAP embedding was computed using the cosine distance on the resulting 50 Harmony 250 components (37). Lastly, an approximate shared nearest neighbors graph was computed on the 251 first 50 Harmony components using the cosine distance with the number of nearest neighbors set 252 to 100, and the resulting graph was partitioned into clusters via Louvain modularity optimization 253 using a resolution of 0.1 (38). 254

255

257

256 2.3.3 scRNA-seq annotation

After clustering, the SingleR package v2.0.0 was used with several different immune 258 reference datasets with known labels to assign a most-likely broad cell type to each cluster (39-259 44). In addition, the Azimuth package was used to map reference labels from an annotated 260 261 dataset of healthy human PBMCs to each cell at multiple levels of granularity (34). Lastly, between-cluster differential expression testing was performed using the Wilcoxon rank-sum test 262 with *p*-values adjusted via the Bonferroni correction. Genes were considered for testing if they 263 264 were expressed by at least 25% of the cells in the cluster being tested, and results were retained if the mean log2 fold-change was greater than 0.25 and the adjusted p-value was less than 0.05 (45, 265 46). After a comparison of the resulting differentially expressed gene sets (DEGs) with canonical 266 marker genes from the literature and an investigation of the unsupervised annotations, a broad 267 cell type identity was manually assigned to each cluster. 268

After subsetting the initial dataset to just the cluster labeled as monocytes, cells with 269 270 confident T-cell labels from Azimuth were filtered out and the data were split into two groups based on whether the cells came from healthy subjects or septic patients. Subcluster analysis was 271 performed on the monocytes from the healthy subjects and septic patients. Briefly, the data were 272 reprocessed and reintegrated as described before, though the number of HVGs was lowered to 273 3,000 and only 30 principal components were used as input to the integration, nonlinear 274 dimension reduction, and clustering routines. In addition, the number of estimated nearest 275 276 neighbors was reduced based on the smaller sizes of the subsets. Any further subclustering of heterogeneous cell types was performed using the same methods. Differential expression testing 277 was again used to identify potential marker gene sets, and a fine cell type label was manually 278 assigned to each cluster. Lastly, the cell type labels were subjected to confirmatory analysis 279 using the available cell surface protein data as needed. 280

281

282 2.3.4 scRNA-seq differential expression

283

Differential expression testing between for each time point versus healthy subjects in the "classically" annotated MDSCs was performed using a pseudobulk approach. Counts across all cells for each patient were aggregated and summed, then the DESeq2 method was applied for differential testing using the muscat R package v1.14.0 (47). The cell-type specific marker gene expression testing on the MDSCs annotated using the "*emergent*" view was performed using the **FindAllMarkers** function in Seurat using the wilcox method.

Differentially expressed testing between sepsis groups was performed using linear mixed 290 291 models. Each gene was tested between comparison groups for M-MDSCs, as they were the only population of MDSCs with a sufficient number of cells (n > 50) per group. Normalized 292 293 expression was used as the response, with a binary indicator for sepsis group as the sole fixed effect. A random intercept was included for each sample, and models were fit via the maximum 294 likelihood estimation using the MixedModels.jl Julia package (48, 49). After recording 295 expression statistics such as mean expression per group, raw fold change, and log2 fold change, 296 the *p*-value of the group difference fixed effect from the linear mixed model was used to 297 determine the significance of differential expression after adjustment using the Holm correction 298 (38, 50). 299

300

2.3.5 Enrichment of genes with high transcriptional activity in MDSCs 302

The unspliced ratio per gene per cell was calculated as (unspliced counts + 1) divided by 303 the (spliced counts + 1), then the mean for each gene was calculated separately for the MDSC 304 subpopulations. Genes having a mean ratio greater than 1.1 were considered as having a high 305 306 degree of active transcription. The gprofiler2 R package v0.2.1 (51) was used to identify significantly enriched biological processes for each set of genes, then a network-based approach 307 was performed to better understand the biological functions using the vissE R package v1.8.0 308 309 (52). Similarities among the enriched processes were computed using the Jaccard index and then used to build an overlap network. Clusters of enriched gene-sets were identified by graph 310 clustering; for each cluster a frequency analysis of words in the gene-set names indicates the 311 most relevant biological functions. 312

313

315

314 2.3.6 scRNA-seq trajectory inference and RNA velocity

After annotating the septic monocytic cells, the data were further subject to only include 316 the cell types thought to be relevant to MDSC development and differentiation: classical and 317 non-classical monocytes, cDCs, and MDSCs. This subset was re-embedded using UMAP, and 318 the cells were reclustered using the re-computed simulated neural network graph as input to the 319 Louvain algorithm (37). After extracting the UMAP parameters from the output of the 320 321 RunUMAP function, we used the uwot R package to regenerate the fitted UMAP model and nearest neighbor data that were generated internally (53). From this output we extracted the 322 UMAP connectivity graph, which is a sparse representation of the fuzzy simplicial data set that 323 can be loosely interpreted as a metric of how likely connections are between cells (37). The raw 324 counts matrices, metadata for cells and genes, nearest neighbor graphs, PCA, Harmony, and 325 UMAP embeddings, and the UMAP connectivity graph were used to generate an AnnData 326 object in Python that exactly matched the preprocessing used when annotating the cells in R (54). 327

328 The preprocessed data were used as input to an RNA velocity estimation workflow built around the scVelo package v0.2.5. After computing first-order moments of the spliced and 329 unspliced counts, the dynamical velocity model was used to estimate per-gene velocities and a 330 cell-level velocity graph, after which the velocities were projected onto the existing UMAP 331 embedding (55, 56). Next, transition probability matrices, absorption probabilities, and initial 332 and terminal cell state likelihoods were estimated based on a weighted kernel of the velocity 333 estimates and UMAP connectivities using the CellRank package v1.5.1 (57). The resulting cell 334 fate probabilities then served as a prior for the estimation of a gene-shared latent time for each 335

cell. Lineage driving genes were identified by estimating the Spearman correlation of each 336 337 gene's expression with absorption probabilities for each identified cell fate. Finally, a directed partitioned graph abstraction was estimated and projected into the existing UMAP embedding 338 339 using the state probability and latent time estimates as priors; these computations were performed using the partition-based graph abstraction (PAGA) algorithm as implemented in 340 v1.9.3 of the Scanpy package (58, 59). In addition, an undirected graph abstraction was used as 341 the initialization for a force-directed graph embedding of the cells, after which the graph 342 abstraction was recomputed on the resulting embedding. This layout of the cells was used to 343 display inter-cell type connectivities, which were estimated as described previously using UMAP 344 (60, 61). 345

Differences in the dynamical model parameters (state probabilities, velocity length and pseudotime, cell stability index, and lineage priming) were tested between septic groups within MDSC subpopulations using a linear mixed model. Specifically, the **nlme** R package v3.1-162 (62) was used to fit a model with fixed effects of cell type, group, and their interaction, and a random intercept for subject. Pairwise testing was then obtained using contrasts of interest (across groups within cell type) with the **emmeans** R package v1.8.7 (63).

353 **3. Results**

354 355

356

352

3.1 MDSC subpopulations initially defined by classical cell surface markers

Here we have used CITE-seq to analyze single-cell transcriptomic profiles of MDSCs in blood from healthy subjects (n=12) and surgical sepsis patients at 4 ± 1 (n=4) and 14-21 (n=9) days after sepsis onset (64). Septic patients at 14-21 days were further divided based on their clinical outcomes at time of sampling, defined as either 'rapid recovery' (n=4) or development of CCI (n=5). CCI was defined as sepsis survivors requiring 14 or more days of ICU care with persistent organ injury. Sex, age, BMI, and comorbidity profiles were similar between cohorts (**Table 1**).

Similar to flow cytometry phenotyping, CITE-seq employs conventional cell surface 364 (Lin⁻HLADR^{low/-} for myeloid cell subpopulations to define E-MDSCs 365 markers CD33⁺CD11b⁺CD14⁻CD15⁻CD66b⁻), PMN-MDSCs (Lin⁻CD33⁺CD11b⁺CD14⁻ and CD15⁺ or 366 CD66b⁺), and M-MDSCs (Lin⁻HLADR^{low/-}CD33⁺CD11b⁺CD14⁺CD15⁻CD66b⁻), as well as 367 CD14⁺CD16⁻ (classical) and CD14^{dim}CD16⁺ (non-classical) monocytes (while removing 368 platelets, erythrocytes, HSPCs, $\gamma\delta$ T cells, and innate lymphoid cells). This is consistent with the 369 classical monolithic view of myeloid differentiation described by Hegde (Fig. 1A) (13). 370 Historically, flow cytometry classification of MDSCs is performed directly on isolated PBMCs 371 (4, 16), and our analysis revealed that PMN-MDSCs made up the majority of MDSCs in isolated 372 PBMCs of representative septic patients, consistent with prior literature (**Table 2**) (4, 16). 373

374 We then evaluated cell proportions using transcriptomics with confirmation via flow cytometry. Myeloid cell enrichment was necessary in this step in order to detect MDSCs in 375 healthy subject samples during CITE-seq as they are a relatively rare population (see Methods 376 Section entitled "Human Blood Collection and Sample Preparation"). Both single-cell 377 transcriptomics and flow cytometry revealed an overall increase in total MDSCs acutely after 378 sepsis (Fig. 1B and Table 3). We plotted the cells via Uniform Manifold Approximation and 379 380 Projection (UMAP) based on timepoint after sepsis (Fig. 1C) and myeloid cell subtype (Fig. **1D**), which revealed heterogeneity of these cells when analyzing their single cell transcriptomes. 381

The classification of MDSCs based on cell surface phenotypes is somewhat dependent on the method of analysis, and as the myeloid enrichment kit (STEMCELL) uses CD33 (and CD33 is expressed on all MDSCs), this was our first inclination that an alternative method of classifying cells by subpopulation would be necessary.

Next, we performed pseudobulk differential gene expression between septic patients at 386 day 4 and days 14-21 post-sepsis diagnosis compared to healthy subjects to assess possible 387 differences among septic groups. Dramatic differences in gene expression within MDSC 388 subpopulations (specifically PMN- and M-MDSCs, which were most abundant) were observed 389 that varied over time (Fig. 2). Considering PMN-MDSCs, by comparing each differential 390 expression test performed against healthy subjects, we found more extreme fold-changes in late 391 sepsis patients who developed CCI compared to acutely septic patients (Fig. 2A, left panel). 392 Conversely, gene expression for late sepsis patients who rapidly recovered returned towards that 393 seen in healthy subjects when compared to both acute sepsis and late sepsis with CCI. Gene 394 expression for rapid recovery and CCI patients compared to healthy subjects also tended to 395 396 diverge (Fig. 2A, middle and right panels). Overall, 52 genes were differentially expressed in PMN-MDSCs from acutely septic patients; however, only three of these genes were also 397 398 significantly differentially expressed in both late sepsis patients who either rapidly recovered or developed CCI (Fig. 2B; Supplemental File 1). The ontology of transcriptional differences 399 among septic patients at different time points also illustrated the heterogeneity of the PMN-400 401 MDSC response over time (Fig. 2C).

The greatest differences in the magnitude of M-MDSC gene expression from healthy subjects compared to septic patients occurred during acute sepsis (day 4) (**Fig. 2D**). In this cohort, 601 genes were differentially expressed in M-MDSCs, and only 31 of these were also significantly differentially expressed in late sepsis patients who either rapidly recovered or developed CCI at days 14-21 (**Fig. 2E**). Gene ontology analysis among M-MDSCs revealed that patients experiencing rapid recovery had over-expression of kinase agents versus oxoacid metabolism when compared to sepsis patients with CCI (**Fig. 2F**).

In summary, transcriptomic analysis comparing healthy subjects, patients day 4 postsepsis, and patients at days 14-21 post-sepsis (combining those who rapidly recovered with those who developed CCI) revealed significant heterogeneity in MDSC transcriptomics. In addition, lymphocyte suppressive activity, specifically suppression of T cell proliferation and T cell cytokine/chemokine production, varied between cohorts (*see below*). MDSCs from both time points after sepsis were dissimilar when comparing their gene expression profiles and significantly enriched biological processes from gene ontology.

416 417

418

3.2 Verifying the immunosuppressive capacity of MDSCs present in sepsis

Our laboratory has previously used cell sorting and subsequent T-cell suppression assays 419 to demonstrate the immunosuppressive capacity of total MDSCs from septic patients (4, 16). 420 Thus, we set out to verify that functionally active PMN- and M-MDSCs were indeed present in 421 the isolated peripheral blood mononuclear cells (PBMCs) of septic individuals, as defined by 422 Gabrilovich, et al (65). Surprisingly, we discovered unexpected cell types in our flow cytometry 423 samples that were supported by single-cell analysis. Historically in the cancer literature, CD15 424 positivity is used to distinguish PMN-MDSCs from M-MDSCs (13). However, in representative 425 septic patients, after identifying CD11b⁺CD33⁺ cells (**Fig. S1A**) and isolating HLA-DR^{-/low} cells 426 to obtain the total MDSC population (Fig. S1B), CD15 was unable to clearly separate MDSC 427

subpopulations (Fig. S1C, bottom panel). Alternatively, CD66b (CEACAM8; a granulocytic 428 429 marker) was able to better delineate MDSC subpopulations (Fig. S1C, top panel) and, thus, was selected to distinguish PMN-MDSCs from PBMCs for functional analysis (Fig. S1D) (19, 20, 430 431 65-67). We undertook bulk CD66b⁺ cell isolation (STEMCELL Technologies, Vancouver); however, although CD14⁻CD15⁺ PMN-MDSCs enrichment was achieved, further analysis of the 432 CD66b⁺-isolated cells demonstrated distinct CD66b^{low} and CD66b^{high} populations (Fig. S2A). 433 Thus, we had enriched CD66b^{low}CD14⁺CD15⁻ M-MDSCs in our gating strategy which was 434 meant to only contain PMN-MDSCs (CD66b^{high}) (Fig. S2B). 435

Functionally, the CD66b⁺ cells isolated from septic patient PBMCs suppressed either
 CD4⁺/CD8⁺ T-lymphocyte cytokine/chemokine production (Fig. S3) or lymphocyte proliferation
 of host CD8⁺ T-lymphocytes (Fig. S4), thereby meeting the criteria of MDSCs. CD66b⁺ MDSCs
 from septic but not healthy subjects altered T-cell cytokine production in response to

- antiCD3/CD28 treatment, including IFN- γ , IL-2, IL-4, IL-10, and IL-17 (**Fig. S3**). Cytokines
- which were analyzed which did not exhibit $CD66b^+$ inhibition in acutely septic patients include
- 442 IL-12, IL-23, and TGF- β . Only CD66b⁺ cells isolated from sepsis patients 14-21 days after
- infection were capable of significantly suppressing CD8⁺ T-lymphocyte proliferation in response
- to CD3/CD28 stimulation (**Fig. S4**). Although we did not see suppression of CD4⁺ T-lymphocyte
- 445 proliferation by CD66b⁺ cells in response to CD3/CD28 stimulation, we did see a significant
- decrease in CD4⁺ T-lymphocyte proliferation stimulated in culture at days 14-21 compared to
- day 4 (**Fig. S5**). This indicates that $CD4^+$ T lymphocytes are incapable of appropriate
- proliferation 2-3 weeks after sepsis (similar to what has been previously reported) (68), and that
 MDSCs at this time point may not be able to further suppress this aspect of CD4⁺ T lymphocyte
 function (22, 68).
- 451

452 3.3 Emergent view of MDSCs and transcriptomic analysis of a novel MDSC 453 subpopulation

454

After our initial steps demonstrated that identification of MDSC subsets based on cell 455 surface markers was potentially problematic in sepsis, we transitioned to cell classification via 456 gene expression for the remainder of our analysis. All cells were clustered based on their 457 transcriptomic profiles (visualized via UMAP (Fig. 3A) with relative percentages of each cell 458 type depicted in **Fig. 3B**). The broad cell types were compared via expression of cell-surface 459 marker genes (Fig. 3C) as well as percentage of spliced mRNA between patient groups (Fig. 460 **3D**). This was followed by careful manual annotation and inspection of canonical marker genes 461 with identification of myeloid cells via differential expression of genes (Fig. 4). As explained by 462 Hegde, et al. (13), there is substantial plasticity within MDSC subpopulations during sepsis 463 which informs the relationship between MDSCs and terminally differentiated effector cells (Fig. 464 5A). Additional marker genes were used to obtain fine-level annotation of myeloid cell types 465 (Fig. 5B). Importantly, four distinct populations of MDSCs were identified via this approach 466 (Fig. 5C), three of which were consistent with classically defined E-, PMN-, and M-MDSCs 467 (65). A novel fourth population was identified in 60% of the late sepsis patients who developed 468 CCI, as well as both of the acutely septic patients who progressed to CCI (Table 4, Fig. 6A). 469 This MDSC subpopulation exhibited gene expression patterns that were partially consistent with 470 both M- and PMN-MDSCs. We thus labeled these cells "hybrid" (H)-MDSCs. Although one of 471 472 the patients with CCI had a much greater number of H-MDSCs than other patients, it should be

noted no H-MDSCs were observed in late sepsis patients who had rapidly recovered, or acutely
septic patients who progressed to rapid recovery (**Table 4**).

The majority of MDSC-specific genes in septic patients were shared by at least two of the 475 476 four subpopulations (66%, n=270 genes), with 36% (n=147 genes) significantly expressed by all four (Fig. 6B, Supplemental File 2). Although the MDSC subpopulations were fairly similar in 477 terms of overlapping genetic expression, we identified seven genes uniquely expressed by H-478 MDSCs: RGDP5, TBL1X, MBNL1, SERF2, ATP5F1E, MT-ND1, and MT-ATP6 (Fig. 6C). Gene 479 expression was downregulated in RANBP2-like and GRIP domain-containing protein 5 480 (RGDP5), transducin (beta)-like 1X-linked (TBL1X), and muscleblind-like splicing regulator 1 481 (MBNL1) (69, 70). TBL1X regulates transcriptomic pathways and is upregulated in malignancy 482 (69). *MBNL1* regulates alternative splicing and can be up- or downregulated depending on the 483 type of cancer (71). Genes with upregulated expression included small EDRK-rich factor 2 484 (SERF2), ATP synthase F1 subunit epsilon (ATP5F1E), NADH-ubiquinone oxidoreductase 485 chain 1 (MT-ND1), and mitochondrially encoded ATP synthase membrane subunit 6 (MT-486 ATP6). The latter three genes encode proteins involved in mitochondrial metabolism and 487 function (72). 488

489 We next sought to identify differential genetic expression between our septic cohorts, specifically looking at differences between MDSCs in late sepsis patients who rapidly recovered 490 and those who developed CCI. For differential expression across sepsis groups, only M-MDSCs 491 492 were sufficiently present per group for fitting a linear mixed model with multiple subjects, as MDSCs are a relatively rare population overall. We identified four differentially expressed genes 493 in M-MSDCs using this method: CD163, IER2, CTSZ, and SNX3 (Fig. 6D). Expression of 494 CD163 (73), a gene responsible for controlling inflammation, was significantly lower in M-495 MDSCs in late sepsis patients with CCI versus acutely septic patients. SNX3 has been identified 496 as a potential septic biomarker (74), and was significantly upregulated in patients with CCI 497 498 compared to acutely septic patients. IER2 was significantly higher expressed in late sepsis patients who rapidly recovered compared to acutely septic patients. IER2 is known to be 499 upregulated in response to external stimuli including infection (75, 76). CTSZ expression was 500 significantly higher in patients with CCI compared to patients who rapidly recovered after sepsis, 501 and has been previously identified as a septic marker in mice (77). 502

The plasticity of the H-MDSC subpopulation is evident in the increased per-cell 503 504 proportion of unspliced mRNA, indicating more active transcription. Only E-MDSCs had a higher proportion of unspliced mRNA in the myeloid compartment (Fig. 7A). To examine 505 factors driving cellular activities, we identified genes with a high average proportion of unspliced 506 mRNA within each cell subpopulation and performed enrichment analysis to identify relevant 507 biological processes. Rather than focusing on individual ontologies, we used a network-based 508 approach to cluster similar significantly enriched biological functions for each MDSC 509 subpopulation (Fig. 7B-E) (52). Not surprisingly, actively transcribed genes in all MDSC 510 511 subpopulations were enriched for activities pertaining to 'immune activation.' While PMN- and M-MDSCs had more biologically distinct functions, H-MDSCs shared enrichment with both cell 512 types, specifically pertaining to pathophysiological septic-related processes including 513 'organonitrogen' and phosphorus-related processes. 514

3.4 Determination of differentiation pathways and cell lineage in septic cohorts

517

Having described the MDSC subpopulations, we next set out to incorporate these 518 519 findings into differentiation pathways of the myeloid compartment in septic patients. Quantifying transcriptional kinetics via RNA velocity estimation revealed complex, fluid relationships 520 521 between MDSC phenotypes (Fig. 8A). As expected, M-MDSCs appeared to serve as the bridge between early immunosuppressive cell types and mature myeloid cells such as monocytes and 522 conventional dendritic cells (cDCs) (Fig. 8B). As our analysis was based on PBMCs, it was not 523 possible to compare the transition from MDSCs to mature granulocytes (PMNs). Estimating the 524 graph connectivity between monocyte-lineage cell types allowed us to quantify the strength of 525 each undirected relationship, and showed that MDSC subpopulations are both highly 526 interconnected and much more internally similar to each other than they are to populations of 527 terminally-differentiated myeloid cells (Figs. 8B-C). 528

After analyzing velocity-inferred cell state transitions performed with CellRank, all E-, 529 PMN-, and the vast majority of M-MDSCs cell states were classified as progenitor-like or 530 transitioning-like (Fig. 8D). Only H-MDSCs contained a significant proportion of cells in a 531 plasticity-like state with high probabilities for both initial and terminal cell states (in which cells 532 remain H-MDSCs) (Fig. 8E) (57). Supporting this, significant variation was observed in the 533 likelihood of an H-MDSC staying an H-MDSC when estimated by absorption probabilities from 534 CellRank, with a mean (SD) probability of 0.33 (0.29) (Fig. 8F). No other cell types were likely 535 to end up as H-MDSCs. To better characterize the biology underlying commitment to the H-536 537 MDSC cell fate, lineage driver genes (genes significantly correlated with the probability of becoming an H-MDSC) were identified by computing Spearman correlations of expression with 538 absorption probabilities. Highly correlated genes were diverse in function and included 539 inflammation-associated genes such as S100A8, -9, and -12, along with immunoregulatory genes 540 ALOX5A, RETN, and IL1R2. 541

Next, we investigated differences in cell states across sepsis groups for each MDSC 542 543 subpopulation. As H-MDSCs were not observed in sepsis patients who experienced rapid recovery, they were not included for this analysis. M-MDSCs were highly consistent between 544 septic patients at day 4 and days 14-21 in terms of their cell states and kinetics (Fig. 9A). 545 Interestingly, PMN-MDSCs displayed the most heterogeneity, specifically in late sepsis patients 546 with CCI compared to both day 4 septic patients and late sepsis patients who rapidly recovered. 547 PMN-MDSCs in late sepsis patients who developed CCI had significantly slower differentiation 548 speed, higher cell state stability, and lower initial state probabilities (Fig. 9B). This is consistent 549 with PMN-MDSCs persisting in CCI compared to patients who rapidly recover after sepsis. E-550 MDSCs in late sepsis patients with CCI also showed significantly lower differentiation 551 progression than acutely septic patients or late sepsis patients who rapidly recovered, along with 552 a higher degree of cell commitment along the differentiation trajectory compared to acutely 553 septic patients (Fig. 9C). 554

As previously stated, CD66b⁺-isolated PBMCs met the criteria of MDSCs in their ability 555 to suppress either T-lymphocyte cytokine/chemokine production or T-lymphocyte proliferation 556 ex vivo (Figs. 5 & 6) (4, 16), although CD66b⁺-isolated PBMCs were not identical in their 557 suppressive activity from acutely septic patients or late time periods after severe infection. 558 Interestingly, whether using cell-surface markers or transcriptomic analysis of the current 559 dataset, differential expression of several key MDSC genes published in the cancer literature did 560 not reach significance and/or were modestly expressed in septic individuals (Fig. 10). For 561 562 example, although there was upregulation of genes in the S100A and MMP superfamilies,

differential expression of *ARG1*, *IL-10*, *NOS2*, and *TGFB1* did not reach significance (although
 transcripts from all genes were detected).

566 **4 Discussion**

567

Since their delineation by Gabrilovich in 2007 (78), MDSCs have been reported in 568 multiple inflammatory diseases in addition to cancer (79). Recently, Hedge et al. described 569 significant heterogeneity among these immune suppressive cells in the myeloid compartment 570 (13). They stated that historically we have had a 'monolithic view' or definition of MDSCs, and 571 that a more complex 'emergent view' is required to better understand these leukocytes (13). In 572 this report, we have taken both conceptual approaches (monolithic and emergent) to analyze 573 574 MDSCs in one of the first cohorts to compare patients with poor (CCI) versus good (rapid recovery) clinical outcomes after surgical sepsis. Importantly, all analyses revealed significant 575 alterations in the evolution of MDSCs after sepsis (i.e. time points) as well as significant 576 differences in the MDSC subpopulations taken from sepsis survivors who rapidly recovered or 577 developed CCI. In classifying MDSCs via gene expression and transcriptomic analysis, we have 578 also identified a novel MDSC subpopulation (H-MDSCs) present only in sepsis survivors with 579 580 CCI and acutely septic patients who progressed to CCI. Finally, even though we have demonstrated in this work and previously (16) that these cells suppressed lymphocyte 581 proliferation to antigenic stimulation (similar to oncologic processes), the MDSCs identified 582 after sepsis do not significantly express many of the well-described genes key to MDSC 583 immunosuppression in other pathologies, most commonly cancer (80). 584

The study of MDSCs has expanded dramatically over the past decade. However, the 585 overwhelming majority of these studies performed using blood samples are from cancer patients; 586 only five studies focus on systemic infection and sepsis (8, 14, 81-83). Although MDSCs are 587 commonly detected in different inflammatory pathologies, there is a gap in research regarding 588 this cell type in the infected or post-infected host. Data are increasingly illustrating the impact of 589 a dysregulated myeloid compartment in patients with poor long-term outcomes, including 590 COVID-19 (84). MDSCs have been identified in these patients, especially those with more 591 severe disease or poor outcomes (85, 86), and are being considered as a target for 592 immunotherapy (87). 593

MDSCs are challenging to define and characterize. As such, cell surface markers and 594 genes historically used to identify MDSC subpopulations were amassed from multiple different 595 596 resources, predominantly from the cancer literature. Surface markers differ between humans and other species, so only human studies could be considered (88, 89). Based on previous work, we 597 began by isolating CD66b⁺ PBMCs as a means to obtain PMN-MDSCs for functional analysis in 598 septic patients and healthy subjects (10). Interestingly, although we found that the purity of the 599 isolation of CD66b⁺ leukocytes (Fig. S1) was very good, and even though CD66b is considered a 600 marker for granulocytes (90), we identified that the $CD66b^+$ population consisted of a mixture of 601 602 PMN- and M-MDSCs (Fig. S2). Although there can be populations of MDSCs that have different levels of both CD14 or CD15 cell surface expression (91), these positively isolated 603 were a combination of CD14⁺CD15⁻CD66b^{low} 604 $CD66b^+$ PBMCs (M-MDSC) and CD15⁺CD66b^{high} (PMN-MDSC) cells. Our CITE-seq data confirmed that CEACAM8 expression 605 was present in multiple myeloid cell populations. This variable MDSC cell surface expression of 606 CD66b in septic patients appears similar to a cell type described in 1998 to define asynchronous 607 608 myelopoiesis in malignant myeloid disorders (92). This highlights some of the difficulty regarding the use of cell surface phenotypes to classify MDSC subtypes after sepsis. 609

Of note, MDSCs are continuing to be described in certain patient populations, including 610 sepsis, through cell surface markers only (93, 94). Although these data may be valid, our analysis 611 would indicate that the traditional "monolithic" definition of MDSCs may not adequately define 612 these plastic, transitory cell populations in critically ill patients with sepsis. Our results do not 613 refute any currently accepted definitions of human MDSCs (including by cell marker phenotype) 614 (10), but rather illustrate the complexity of the myelodysplasia that occurs after human sepsis, 615 and the shortcomings of cell surface markers alone to identify myeloid cell types after severe 616 infection. In addition, other immunosuppressive cells exist in the PBMCs of whole blood from 617 septic human patients, specifically low-density PMNs and exhausted monocytes (95, 96). This 618 work, and our current results, indicate an immediate compelling need for more refined and 619 nuanced descriptions and definitions of the myeloid compartment after sepsis. 620

Veglia et al. previously described transcriptomic differences between MDSCs and 621 terminally differentiated monocytes and neutrophils (66). Additional guidelines for 622 characterization and nomenclature of MDSCs based on cell surface phenotypes have been 623 proposed, although the same central resource does not appear to exist for single-cell 624 transcriptomic signatures of different MDSC subpopulations (65, 97). However, specific genes 625 626 have been described in the literature. In cancer, STAT3 is important for the T-cell suppression exerted by MDSCs (98). STAT1, -5, and -6 are also important in the regulation of arginase 627 activity, although this may be more pertinent for cancer than sepsis based on the subdued level of 628 ARG1 expression in MDSCs identified from our septic patients (Fig. 10) (98). It should also be 629 noted that different subpopulations than the canonical PMN- and M-MDSCs have been 630 previously described, including Eo-MDSCs (with eosinophilic characteristics) and fibrocystic 631 MDSCs (99, 100). 632

A population of H-MDSCs was found when using the "emergent" classification system 633 of MDSCs via genetic expression in order to classify cell types (Fig. 5C). All four MDSC 634 subpopulations appeared strongly interrelated and our data indicated that these cells are likely 635 plastic in their myeloid state after sepsis (Fig. 6B) (13). As to why we classified these cells as 636 unique from previously defined MDSC subpopulations, H-MDSCs express many similar genes 637 as PMN-MDSCs, although the average expression of these genes tends to be lower, such as with 638 IL1R2, CST7 and MMP8/9. H-MDSCs also share substantial overlap with M-MDSCs, with 639 higher expression in sepsis of genes like S100A8/9 and DNAH17 (Fig. 10). H-MDSCs may be an 640 intermediary between MDSC subpopulations, and their presence in CCI further reveals the 641 plasticity of myeloid differentiation in sepsis (Fig. 8). Although MDSC subpopulations share a 642 similar phenotype after sepsis, their function and transcriptomic patterns are distinct. Thus, after 643 sepsis, 'a MDSC is not a MDSC,' and there is a unique expression of myelodysplasia after severe 644 infection depending on both host and outcome. These data support the concept that targeted 645 therapeutic strategies will be required within these sepsis phenotypes given the heterogenic 646 response of the myeloid compartment to sepsis. 647

This study was limited by the number of patients in each study arm; however, our sample size estimates were similar to past publications in the field (14, 101). This is also a singleinstitution study in which treatment of sepsis is standardized but may differ compared to other institutions. Additionally, we did not stratify septic patients by septic source. Future directions include stratification of our patient cohorts by infection source and demographic information such as age, sex, and ethnicity/race to determine confounding factors which may have affected our analysis by different clinical outcomes after sepsis.

In summary, we have determined that the post-septic myeloid compartment is complex 655 and includes a unique MDSC subpopulation that has not been previously described. Importantly, 656 the heterogeneous response of the blood myeloid compartment to sepsis varies based on time and 657 658 clinical outcome (CCI vs rapid recovery) and demonstrates that cell surface markers may not be a reliable indicator of circulating myeloid cell types after sepsis. Sepsis, like many other 659 pathologies, requires a precision/personalized medical approach in order to improve host 660 outcomes (22). Our work reveals specific cell types and pathways that could be modified in 661 patients at risk of poor outcomes after sepsis (CCI) to convert them to a phenotype of rapid 662 recovery. 663

665 **5 References**

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.,
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. **315**, 801-10 (2016).

- 669 2. Stortz JA, Mira JC, Raymond SL, Loftus TJ, Ozrazgat-Baslanti T, Wang Z, et al.,
- Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients. *J Trauma Acute Care Surg.* **84**, 342-9 (2018).
- 672 3. Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moreno C, Scumpia PO, Laface DM, et al.,
 673 A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. *Mol Med.* 17, 281-
- 674 92 (2011).
- 4. Mathias B, Delmas AL, Ozrazgat-Baslanti T, Vanzant EL, Szpila BE, Mohr AM, et al.,
 Human Myeloid-derived Suppressor Cells are Associated With Chronic Immune Suppression
 After Severe Sepsis/Septic Shock. *Ann Surg.* 265, 827-34 (2017).
- Horiguchi H, Loftus TJ, Hawkins RB, Raymond SL, Stortz JA, Hollen MK, et al., Innate
 Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its
 Implications for Therapy. *Front Immunol.* 9, 595 (2018).
- 681 6. Kondo A, Yamashita T, Tamura H, Zhao W, Tsuji T, Shimizu M, et al., Interferon-
- gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via
 nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. *Blood.* 116, 1124-31
 (2010).
- 685 7. Kondo Y, Tachikawa E, Ohtake S, Kudo K, Mizuma K, Kashimoto T, et al.,
- Inflammatory cytokines decrease the expression of nicotinic acetylcholine receptor during the cell maturation. *Mol Cell Biochem.* **333**, 57-64 (2010).
- 8. Uhel F, Azzaoui I, Gregoire M, Pangault C, Dulong J, Tadie JM, et al., Early Expansion
 of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of
- Nosocomial Infections in Patients with Sepsis. *Am J Respir Crit Care Med.* 196, 315-27 (2017).
 9. Coudereau R, Waeckel L, Cour M, Rimmele T, Pescarmona R, Fabri A, et al.,
- Emergence of immunosuppressive LOX-1+ PMN-MDSC in septic shock and severe COVID-19
- patients with acute respiratory distress syndrome. *Journal of leukocyte biology*. **111**, 489-96 (2022).
- Veglia F, Sanseviero E, Gabrilovich DI, Myeloid-derived suppressor cells in the era of
 increasing myeloid cell diversity. *Nat Rev Immunol.* 21, 485-98 (2021).
- 697 11. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al.,
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization
 standards. *Nat Commun.* 7, 12150 (2016).
- 12. Mira JC, Cuschieri J, Ozrazgat-Baslanti T, Wang Z, Ghita GL, Loftus TJ, et al., The
- Epidemiology of Chronic Critical Illness After Severe Traumatic Injury at Two Level-One
 Trauma Centers. *Crit Care Med.* 45, 1989-96 (2017).
- Hegde S, Leader AM, Merad M, MDSC: Markers, development, states, and unaddressed
 complexity. *Immunity*. 54, 875-84 (2021).
- 14. Darden DB, Bacher R, Brusko MA, Knight P, Hawkins RB, Cox MC, et al., Single-Cell
- 706 RNA-seq of Human Myeloid-Derived Suppressor Cells in Late Sepsis Reveals Multiple Subsets
- With Unique Transcriptional Responses: A Pilot Study. *Shock (Augusta, Ga.* 55, 587-95 (2021).
- 15. Loftus TJ, Mira JC, Ozrazgat-Baslanti T, Ghita GL, Wang Z, Stortz JA, et al., Sepsis and
- 709 Critical Illness Research Center investigators: protocols and standard operating procedures for a

- prospective cohort study of sepsis in critically ill surgical patients. *BMJ Open.* **7**, e015136
- 711 (2017).
- 16. Hollen MK, Stortz JA, Darden D, Dirain ML, Nacionales DC, Hawkins RB, et al.,
- Myeloid-derived suppressor cell function and epigenetic expression evolves over time after surgical sepsis. *Crit Care.* **23**, 355 (2019).
- 17. Brakenridge SC, Efron PA, Cox MC, Stortz JA, Hawkins RB, Ghita G, et al., Current
- Field Epidemiology of Surgical Sepsis: Discordance Between Inpatient Mortality and 1-year
- 717 Outcomes. Ann Surg. **270**, 502-10 (2019).
- 18. Darden DB, Brakenridge SC, Efron PA, Ghita GL, Fenner BP, Kelly LS, et al.,
- 719 Biomarker Evidence of the Persistent Inflammation, Immunosuppression and Catabolism
- Syndrome (PICS) in Chronic Critical Illness (CCI) After Surgical Sepsis. Ann Surg. 274, 664-73
 (2021).
- 19. Trellakis S, Bruderek K, Hutte J, Elian M, Hoffmann TK, Lang S, et al., Granulocytic
- myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with
- serum concentrations of colony-stimulating factors in head and neck cancer. *Innate Immun.* 19,
 328-36 (2013).
- Blanter M, Gouwy M, Struyf S, Studying Neutrophil Function in vitro: Cell Models and
 Environmental Factors. *J Inflamm Res.* 14, 141-62 (2021).
- 21. Schenz J, Obermaier M, Uhle S, Weigand MA, Uhle F, Low-Density Granulocyte
- Contamination From Peripheral Blood Mononuclear Cells of Patients With Sepsis and How to Remove It - A Technical Report. *Front Immunol.* **12**, 684119 (2021).
- 731 22. Darden DB, Kelly LS, Fenner BP, Moldawer LL, Mohr AM, Efron PA, Dysregulated 732 Immunity and Immunotherapy after Sepsis. *J Clin Med.* **10**, (2021).
- 733 23. Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al., Massively
- parallel digital transcriptional profiling of single cells. *Nat Commun.* **8**, 14049 (2017).
- Andrews S. A quality control tool for high througput sequence data: Babraham
 Bioinformatics; 2010 [Available from:
- 737 https://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
- 738 25. Gaidatzis D, Burger L, Florescu M, Stadler MB, Analysis of intronic and exonic reads in
- RNA-seq data characterizes transcriptional and post-transcriptional regulation. *Nat Biotechnol.* **33**, 722-9 (2015).
- 741 26. Srivastava A, Malik L, Sarkar H, Patro R, A Bayesian framework for inter-cellular
- information sharing improves dscRNA-seq quantification. *Bioinformatics*. **36**, i292-i9 (2020).
- 743 27. Srivastava A, Malik L, Smith T, Sudbery I, Patro R, Alevin efficiently estimates accurate
 744 gene abundances from dscRNA-seq data. *Genome Biol.* 20, 65 (2019).
- He D, Zakeri M, Sarkar H, Soneson C, Srivastava A, Patro R, Alevin-fry unlocks rapid,
 accurate and memory-frugal quantification of single-cell RNA-seq data. *Nat Methods*. 19, 316-
- 747 22 (2022).
- R: A language and environment for statistical computing.: The R Foundation; 2022
 [Available from: https://www.r-project.org/.
- 750 30. Python Language Reference: Python; 2019 [Available from: https://docs.python.org/3/.
- Zhu A, Srivastava A, Ibrahim JG, Patro R, Love MI, Nonparametric expression analysis
 using inferential replicate counts. *Nucleic Acids Res.* 47, e105 (2019).
- 753 32. Griffiths JA, Richard AC, Bach K, Lun ATL, Marioni JC, Detection and removal of
- barcode swapping in single-cell RNA-seq data. *Nat Commun.* **9**, 2667 (2018).

33. Lun ATL, Riesenfeld S, Andrews T, Dao TP, Gomes T, participants in the 1st Human

- Cell Atlas J, et al., EmptyDrops: distinguishing cells from empty droplets in droplet-based
- single-cell RNA sequencing data. *Genome Biol.* **20**, 63 (2019).
- Hao Y, Hao S, Andersen-Nissen E, Mauck WM, 3rd, Zheng S, Butler A, et al., Integrated
 analysis of multimodal single-cell data. *Cell.* 184, 3573-87 e29 (2021).
- 760 35. Tirosh I, Izar B, Prakadan SM, Wadsworth MH, 2nd, Treacy D, Trombetta JJ, et al.,
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science*.
 352, 189-96 (2016).
- 763 36. Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al., Fast, sensitive 764 and accurate integration of single-cell data with Harmony. *Nat Methods*. **16**, 1289-96 (2019).
- 37. McInnes LH, J.; Melville, J. . UMAP: Uniform Manifold Approximation and Projection
 for Dimension Reduction Cornell University2018 [Available from:
- 767 https://arxiv.org/abs/1802.03426.
- 768 38. Blondel VD, Guillaume J-L, Lambiotte R, Lefebvre E, Fast unfolding of communities in 769 large networks. *Journal of Statistical Mechanics: Theory and Experiment.* **2008**, P10008 (2008).
- 770 39. Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, et al., Reference-based analysis of
- lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat Immunol.* 20, 16372 (2019).
- 40. Schmiedel BJ, Singh D, Madrigal A, Valdovino-Gonzalez AG, White BM, Zapardiel-
- Gonzalo J, et al., Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression.
 Cell. 175, 1701-15 e16 (2018).
- 41. Martens JH, Stunnenberg HG, BLUEPRINT: mapping human blood cell epigenomes. *Haematologica*. 98, 1487-9 (2013).
- 42. Consortium EP, An integrated encyclopedia of DNA elements in the human genome. *Nature*. 489, 57-74 (2012).
- 43. Mabbott NA, Baillie JK, Brown H, Freeman TC, Hume DA, An expression atlas of
- human primary cells: inference of gene function from coexpression networks. *BMC Genomics*.
 14, 632 (2013).
- 44. Monaco G, Lee B, Xu W, Mustafah S, Hwang YY, Carre C, et al., RNA-Seq Signatures
 Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell
- 785 Types. *Cell Rep.* **26**, 1627-40 e7 (2019).
- 45. Bauer DF, Constructing Confidence Sets Using Rank Statistics. *Journal of the American Statistical Association.* 67, 687-90 (1972).
- 46. Miller RG. Simultaneous Statistical Inference. Second ed: Springer International
 Publishing; 2012. 315 p.
- 790 47. Crowell HL, Soneson C, Germain PL, Calini D, Collin L, Raposo C, et al., muscat
- detects subpopulation-specific state transitions from multi-sample multi-condition single-cell
 transcriptomics data. *Nat Commun.* 11, 6077 (2020).
- 48. Benzanson JE, A; Karpinski, S; Shah, VB, Julia: A Fresh Approach to Numerical
 Computing. *SIAM Rev.* 59, 65-98 (2017).
- 49. Bates DA, P; Kleinschmidt, D; Calderon, JBS; Noack, A; Kelman, T; Bouchet-Valat, M;
- Gagnon, YL; Babayan, S; Mogensen, PK; Piibeleht, M; Hatherly, M; Saba, E; Baldassari, A.
- JuliaStats/MixedModels.jl: v2.3.0 (v.2.3.0): Zenodo; 2020 [Available from:
- 798 <u>https://doi.org/10.5281/zenodo.3727845</u>.
- 50. Holm S, A simple sequentially rejective multiple test procedure. *Scand J Stat.* **6**, 65-70 (1979).

- 51. Kolberg L, Raudvere U, Kuzmin I, Vilo J, Peterson H, gprofiler2 -- an R package for
- gene list functional enrichment analysis and namespace conversion toolset g:Profiler. *F1000Res*.
 9, (2020).
- 804 52. Bhuva DD. vissE: Visualising Set Enrichment Analysis Results 2022 [Available from:
 805 <u>https://davislaboratory.github.io/vissE</u>.
- 806 53. Melville J. uwot: The Uniform Manifold Approximation and Projection (UMAP) method
- for dimensionality reduction. 2022 [Available from: <u>https://CRAN.R-project.org/package=uwot</u>.
- 54. Virshup I, Rybakov S, Theis FJ, Angerer P, Wolf FA, anndata: Annotated data. *bioRxiv*.
 2021.12.16.473007 (2021).
- 55. La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, et al., RNA
 velocity of single cells. *Nature*. 560, 494-8 (2018).
- 56. Bergen V, Lange M, Peidli S, Wolf FA, Theis FJ, Generalizing RNA velocity to transient
 cell states through dynamical modeling. *Nat Biotechnol.* 38, 1408-14 (2020).
- 57. Lange M, Bergen V, Klein M, Setty M, Reuter B, Bakhti M, et al., CellRank for directed single-cell fate mapping. *Nat Methods*. **19**, 159-70 (2022).
- 58. Wolf FA, Hamey FK, Plass M, Solana J, Dahlin JS, Gottgens B, et al., PAGA: graph
- abstraction reconciles clustering with trajectory inference through a topology preserving map of
 single cells. *Genome Biol.* 20, 59 (2019).
- 59. Wolf FA, Angerer P, Theis FJ, SCANPY: large-scale single-cell gene expression data analysis. *Genome Biol.* **19**, 15 (2018).
- 60. Jacomy M, Venturini T, Heymann S, Bastian M, ForceAtlas2, a continuous graph layout algorithm for handy network visualization designed for the Gephi software. *PLoS One*. **9**, e98679 (2014).
- 61. Fruchterman TMJ, Reingold EM, Graph drawing by force-directed placement. *Software: Practice and Experience*. **21**, 1129-64 (1991).
- 62. Pinheiro JCBDMRCT. nlme: Linear and Nonlinear Mixed Effects Models 2023
 [Available from: https://CRAN.R-project.org/package=nlme.
- 63. Lenth RVBBB, P.; Gine-Vazquez, I.; Herve, M.; Jung, M.; Love, J.; Miguez, F.; Riebl,
- H. and Singmann, H. emmeans: Estimated Marginal Means, aka Least-Squares Means 2023
- 830 [Available from: <u>https://CRAN.R-project.org/package=emmeans</u>.
- 831 64. Stoeckius M, Hafemeister C, Stephenson W, Houck-Loomis B, Chattopadhyay PK,
- Swerdlow H, et al., Simultaneous epitope and transcriptome measurement in single cells. *Nat Methods.* 14, 865-8 (2017).
- 834 65. Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, et al.,
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization
- standards. *Nature Communications*. **7**, (2016).
- 66. Veglia F, Sanseviero E, Gabrilovich DI, Myeloid-derived suppressor cells in the era of
 increasing myeloid cell diversity. *Nature Reviews Immunology*. 21, 485 98 (2021).
- 67. Gabrilovich DI, Myeloid-Derived Suppressor Cells. *Cancer Immunol Res.* **5**, 3-8 (2017).
- 68. Luperto M, Zafrani L, T cell dysregulation in inflammatory diseases in ICU. *Intensive Care Med Exp.* 10, 43 (2022).
- 842 69. Pray BA, Youssef Y, Alinari L, TBL1X: At the crossroads of transcriptional and
- posttranscriptional regulation. *Exp Hematol.* **116**, 18-25 (2022).
- 844 70. Itskovich SS, Gurunathan A, Clark J, Burwinkel M, Wunderlich M, Berger MR, et al.,
- MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. *Nat*
- 846 *Commun.* **11**, 2369 (2020).

- Zhang O, Wu Y, Chen J, Tan F, Mou J, Du Z, et al., The Regulatory Role of Both 847 71. MBNL1 and MBNL1-AS1 in Several Common Cancers. Curr Pharm Des. 28, 581-5 (2022). 848 Li X, Li Y, Yu Q, Qian P, Huang H, Lin Y, Metabolic reprogramming of myeloid-849 72. 850 derived suppressor cells: An innovative approach confronting challenges. J Leukoc Biol. 110, 257-70 (2021). 851 Santos SS, Carmo AM, Brunialti MK, Machado FR, Azevedo LC, Assuncao M, et al., 852 73. Modulation of monocytes in septic patients: preserved phagocytic activity, increased ROS and 853 NO generation, and decreased production of inflammatory cytokines. Intensive Care Med Exp. 4, 854 5 (2016). 855 74. Gong FC, Ji R, Wang YM, Yang ZT, Chen Y, Mao EQ, et al., Identification of Potential 856 857 Biomarkers and Immune Features of Sepsis Using Bioinformatics Analysis. Mediators Inflamm. 2020, 3432587 (2020). 858 75. Wu W, Zhang X, Lv H, Liao Y, Zhang W, Cheng H, et al., Identification of immediate 859 early response protein 2 as a regulator of angiogenesis through the modulation of endothelial cell 860 motility and adhesion. Int J Mol Med. 36, 1104-10 (2015). 861 Kyjacova L, Saup R, Ronsch K, Wallbaum S, Dukowic-Schulze S, Foss A, et al., IER2-862 76. induced senescence drives melanoma invasion through osteopontin. Oncogene. 40, 6494-512 863 (2021). 864 Chung TP, Laramie JM, Meyer DJ, Downey T, Tam LH, Ding H, et al., Molecular 77. 865 866 diagnostics in sepsis: from bedside to bench. J Am Coll Surg. 203, 585-98 (2006). Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, et 78. 867 al., The terminology issue for myeloid-derived suppressor cells. *Cancer Res.* 67, 425; author 868 reply 6 (2007). 869 Veglia F, Perego M, Gabrilovich D, Myeloid-derived suppressor cells coming of age. Nat 870 79. Immunol. 19, 108-19 (2018). 871 872 80. Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al., Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 873 6, 362 (2021). 874 Kotze LA, van der Spuy G, Leonard B, Penn-Nicholson A, Musvosvi M, McAnda S, et 875 81. al., Targeted Gene Expression Profiling of Human Myeloid Cells From Blood and Lung 876 Compartments of Patients With Tuberculosis and Other Lung Diseases. Front Immunol. 13, 877 878 839747 (2022). Dean MJ, Ochoa JB, Sanchez-Pino MD, Zabaleta J, Garai J, Del Valle L, et al., Severe 879 82. COVID-19 Is Characterized by an Impaired Type I Interferon Response and Elevated Levels of 880 Arginase Producing Granulocytic Myeloid Derived Suppressor Cells. Front Immunol. 12, 881 695972 (2021). 882 Chen L, Jin S, Yang M, Gui C, Yuan Y, Dong G, et al., Integrated Single Cell and Bulk 883 83. RNA-Seq Analysis Revealed Immunomodulatory Effects of Ulinastatin in Sepsis: A Multicenter 884 885 Cohort Study. Front Immunol. 13, 882774 (2022). Schulte-Schrepping J, Reusch N, Paclik D, Bassler K, Schlickeiser S, Zhang B, et al., 84. 886 Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell. 182, 1419-40 887 888 e23 (2020). Kiaee F, Jamaati H, Shahi H, Roofchayee ND, Varahram M, Folkerts G, et al., 889 85. Immunophenotype and function of circulating myeloid derived suppressor cells in COVID-19 890
- 891 patients. *Sci Rep.* **12**, 22570 (2022).

86. Xu G, Oi F, Li H, Yang O, Wang H, Wang X, et al., The differential immune responses 892 to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. Cell Discov. 6, 73 893 (2020).894 895 87. Rowlands M, Segal F, Hartl D, Myeloid-Derived Suppressor Cells as a Potential Biomarker and Therapeutic Target in COVID-19. Front Immunol. 12, 697405 (2021). 896 Fridlender ZG, Sun J, Mishalian I, Singhal S, Cheng G, Kapoor V, et al., Transcriptomic 897 88. analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor 898 cells and normal neutrophils. PLoS One. 7, e31524 (2012). 899 Millrud CR, Bergenfelz C, Leandersson K, On the origin of myeloid-derived suppressor 900 89. cells. Oncotarget. 8, 3649-65 (2017). 901 McKenna E, Mhaonaigh AU, Wubben R, Dwivedi A, Hurley T, Kelly LA, et al., 902 90. Neutrophils: Need for Standardized Nomenclature. Front Immunol. 12, 602963 (2021). 903 91. Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, et al., A 904 circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent 905 prognostic/predictive factor in untreated non-small lung cancer patients. J Immunol Res. 2014, 906 659294 (2014). 907 Hansen I, Meyer K, Hokland P, Flow cytometric identification of myeloid disorders by 908 92. asynchronous expression of the CD14 and CD66 antigens. European journal of haematology. 61, 909 910 339-46 (1998). 911 93. Feng S, Cui Y, Zhou Y, Shao L, Miao H, Dou J, et al., Continuous renal replacement therapy attenuates polymorphonuclear myeloid-derived suppressor cell expansion in pediatric 912 severe sepsis. Front Immunol. 13, 990522 (2022). 913 914 94. De Zuani M, Hortova-Kohoutkova M, Andrejcinova I, Tomaskova V, Sramek V, Helan M, et al., Human myeloid-derived suppressor cell expansion during sepsis is revealed by 915 unsupervised clustering of flow cytometric data. Eur J Immunol. 51, 1785-91 (2021). 916 917 95. Sun R, Huang J, Yang Y, Liu L, Shao Y, Li L, et al., Dysfunction of low-density 918 neutrophils in peripheral circulation in patients with sepsis. Sci Rep. 12, 685 (2022). 919 Pradhan K, Yi Z, Geng S, Li L, Development of Exhausted Memory Monocytes and 96. 920 Underlying Mechanisms. Front Immunol. 12, 778830 (2021). Bergenfelz C, Leandersson K, The Generation and Identity of Human Myeloid-Derived 921 97. Suppressor Cells. Front Oncol. 10, 109 (2020). 922 923 98. Condamine T, Gabrilovich DI, Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32, 19-25 (2011). 924 Goldmann O, Beineke A, Medina E, Identification of a Novel Subset of Myeloid-Derived 925 99. Suppressor Cells During Chronic Staphylococcal Infection That Resembles Immature 926 Eosinophils. The Journal of Infectious Diseases. 216, 1444-51 (2017). 927 Zhang H, Maric I, DiPrima MJ, Khan J, Orentas RJ, Kaplan RN, et al., Fibrocytes 928 100. 929 represent a novel MDSC subset circulating in patients with metastatic cancer. Blood. 122, 1105-930 13 (2013). Darden DB, Dong X, Brusko MA, Kelly L, Fenner B, Rincon JC, et al., A Novel Single 101. 931 Cell RNA-seq Analysis of Non-Myeloid Circulating Cells in Late Sepsis. Front Immunol. 12, 932 696536 (2021). 933 934

935 6 Figure Legends

936

Figure 1. Single-cell analysis of myeloid cells using surface protein makers. (A) Illustration 937 938 representing the historical/classic/monolithic definition of MDSCs. E-, PMN-, and M-MDSCs are the predominant subpopulations with distinct phenotypes and functions (modified from 939 Hegde et al. (13)). (B) Cell proportions of monocyte subtypes and MDSCs relative to overall 940 monocytic cells are shown for healthy subjects ("Healthy") (n=12), septic patients 4 days 941 following diagnosis ("Day 4 ± 1 ") (n=4), and septic patients at days 14-21 (separated into those 942 experiencing chronic critical illness ("CCI") (n=5) or those who rapidly recovered ("RAP") 943 (n=4)). (C) UMAP embedding of single-cell transcriptomes of peripheral blood mononuclear 944 cells (PBMCs). Cells are colored by the timepoint at which the samples were taken. Samples 945 from day 4 and days 14-21 are from septic patients. (D) Similar to (C), with cells colored by cell 946 type. M: monocytic, PMN: granulocytic, E: early. 947

948

Figure 2. Analysis via CITE-seq of differential gene expression of PMN- and M-MDSC 949 subpopulations at different time points relative to healthy subjects. (A) Within PMN-950 951 MDSCs, gene expression of twelve healthy subjects (baseline) was compared with septic patients at day 4 ("Day 4 ± 1 ") (n=4) and septic patients at days 14-21 (subdivided into chronic critical 952 illness ("CCI") (n=5) and rapid recovery ("RAP") (n=4)). Differential expression results relative 953 954 to healthy subjects were compared for each pair of septic time points (left panel: day 4 vs CCI, middle panel: day 4 vs RAP, right panel: RAP vs CCI). The x-axis is the absolute difference in 955 the *p*-value per gene ($|\Delta p$ -value|) and the y-axis is the difference in log fold-change ($\Delta \log FC$). 956 The colored points represent genes that were differentially expressed in a single group or for 957 both groups (p-value < 0.01). (B) Venn diagram of genes with overlapping significant 958 differential expression (p-value < 0.01). (C) Enrichment results of significant genes representing 959 the gene ontology biological processes. The y-axis is the negative log (base 10) of the p-value (-960 log₁₀(pvalue)). (**D-F**) Similar to (**A-C**) for M-MDSCs. PMN: granulocytic, M: monocytic. 961

962

Figure 3. UMAP embeddings of peripheral blood mononuclear cells (PBMCs). (A) Cells are 963 colored by the time point at which the samples were taken. Samples from acutely septic patients 964 ("Day 4 ± 1 ") and late sepsis patients who either developed chronic critical illness ("CCI") or 965 experienced rapid recovery ("RAP"). (B) Cells are colored by septic cohort. Late sepsis patients 966 at day 14-21 are separated into two groups denoted "CCI" (chronic critical illness) and "RAP" 967 (rapid recovery) based on their response to the sepsis. (C) Expression of surface markers on 968 subtypes of PBMCs. (D) The left panel denotes percentages of spliced mRNA in different cell 969 types separated by patient cohort. The right panel denotes overall unspliced mRNA across cell 970 types by patient cohort. B: B cells, NK: natural killer cells, HSPC: hematopoietic stem and 971 972 progenitor cells, pDC: plasmacytoid dendritic cells.

973

Figure 4. Marker gene expression across myeloid cell types in septic patients. A dot plot shows scaled mean expression of the top seven most significant differentially expressed genes (DEGs) in each myeloid cell type prior to fine-level annotation for MDSC subpopulations. Point radius indicates the percentage of cells with nonzero expression, and color denotes relatively higher or lower mean expression across cell types. Testing was performed with the Wilcox test, and genes were ranked by adj. *p*-value after Bonferroni correction. CD14⁺: classical monocyte,

CD16⁺: non-classical monocyte, MK: megakaryocyte, cDC: conventional dendritic cells, infl.:
 inflammatory, M: monocytic, E: early, PMN: granulocytic.

982

983 Figure 5. "Emergent" view and annotation of myeloid cell subpopulations in septic patients. (A) Illustration representing the "emergent" definition of MDSCs, incorporating the 984 plasticity and heterogeneity of the myeloid compartment (modified from Hegde, et al (13)). (B) 985 Fine cell type annotations within cells from septic patients that were broadly annotated as 986 monocytes. The x-axis includes the different myeloid cell subtypes. The y-axis includes genes 987 which were most highly expressed by each cell subtype. The scaled mean expression is denoted 988 by the color of the dots, and the percentages of cells expressing the genes are represented by the 989 size of the dots. (C) UMAP plots of cells of the four distinct subpopulations of MDSCs stratified 990 by acutely septic patients ("Day 4 ± 1 ") (n=4), late sepsis patients who developed chronic critical 991 illness ("CCI") (n=5) or experienced rapid recovery ("RAP") (n=4). This includes cells 992 consistent with early (E-) MDSCs, granulocytic (PMN-) MDSCs, monocytic (M-) MDSCs, and a 993 population of cells with characteristics of both M- and PMN-MDSCs, labeled hybrid (H-) 994 995 MDSCs. MK: megakaryocyte, cDC: conventional dendritic cell, infl.: inflammatory.

996

Figure 6. Characterizing data-driven subpopulations of MDSCs. (A) Relative frequencies of 997 MDSCs by subpopulation. Percent of cells defined by transcriptomic analysis and gene 998 999 expression, rather than cell surface markers. Grouped by acutely septic patients ("Day 4 ± 1 ") (n=4) and late sepsis patients who developed chronic critical illness ("CCI") (n=5) or 1000 experienced rapid recovery ("RAP") (n=4). (B) Diagram of significant marker genes for each 1001 1002 MDSC subpopulation were determined in the pooled septic patients. (C) UMAP plots of all MDSCs are shown for the seven genes that were unique markers of gene expression in the H-1003 1004 MDSC subpopulation compared to all other MDSCs. Scaled expression represented by heat map 1005 of each gene. (D) Differential expression testing between septic groups in M-MDSCs revealed four genes that were significant. Y-axis is log (expression +1). Asterisks represent p-value 1006 1007 cutoffs of 0.05 and 0.001, respectively, obtained from the mixed model analysis. M: monocytic, 1008 PMN: granulocytic, E: early, H: hybrid.

1009

Figure 7. Larger proportions of unspliced mRNA in E- and H- MDSCs. (A) Distribution of 1010 1011 unspliced mRNA percent across myeloid cell types. (B-E) Gene-set enrichment analysis of genes having high proportions of unspliced mRNA within each MDSC subpopulation. The left panel 1012 shows the gene-set network and clustering of significantly enriched biological processes. The 1013 1014 right panels show word clouds for each biologically similar cluster (a general cluster of highlevel biological processes was present for each cell-type and omitted). E: early, H: hybrid, M: 1015 monocytic, PMN: granulocytic, CD16⁺: non-classical monocyte, CD14⁺: classical monocyte, 1016 1017 MK: megakaryocyte, cDC: conventional dendritic cell, infl.: inflammatory.

1018

Figure 8. Topology of myeloid differentiation and plasticity in septic patients. (A) Myeloid cell smoothed RNA velocity estimates projected onto UMAP. Arrows represent differentiation potential. (B) Undirected partition-based graph abstraction (PAGA) of myeloid cell types. Line width/color between cell types denote relationship strength. Nodes colored by cell type. (C) Arrow directions represent differentiation potential. Arrow widths denote strength of connectivities between cell types. Arrow manually added indicating PMN-MDSC differentiation into granulocytes. (D) Cell state probabilities shown together for M-, PMN-, and E-MDSCs with

all other cells in gray. (E) Similar to (D) with H-MDSCs in red. (F) H-MDSC cell fate absorption probabilities. cDC: conventional dendritic cell, infl.: inflammatory, $CD16^+$: nonclassical monocyte, $CD14^+$: classical monocyte, M: monocytic, H: hybrid, PMN: granulocytic, E: early.

1030

Figure 9. Differences in PMN-, E-, and M-MDSCs across septic time-points. (A) Cell dynamic parameters estimated from CellRank were compared across cells from septic patients at Day 4 ± 1 (acute sepsis) (n=4), patients at day 14-21 who rapidly recovered ("RAP") (n=4), and patients at day 14-21 who developed chronic critical illness ("CCI") (n=5) in M-MDSCs. (B-C) Similar to (A) for PMN-MDSCs and E-MDSCs, respectively. Significant p-values (< 0.05) were obtained from fitting a linear mixed model. E: early, PMN: granulocytic, H: hybrid, M: monocytic.

1038

Figure 10. Canonical MDSC genes in immunosuppressive cell subpopulations in septic patients. Heatmap of scaled expression of canonical genes identified in the current MDSC literature. Cells in the four identified MDSC subpopulations are denoted in the colored key. Genes were arranged using hierarchical clustering with complete linkage. Patient groups include acutely septic patients ("Day 4 ± 1 ") (n=4) and late sepsis patients who developed chronic critical illness ("CCI") (n=5) or experienced rapid recovery ("RAP") (n=4). M: monocytic, PMN: granulocytic, E: early, H: hybrid.

1046

1048

1047 **7 Tables**

Table 1. Patient characteristics between cohorts. Cohorts are healthy control patients, acutely septic patients, and late sepsis patients who experienced rapid recovery (RAP) and chronic critical illness (CCI). BMI: body mass index, CCI: Charlson comorbidity index, COPD: chronic obstructive pulmonary disease, DM: diabetes mellitus, HTN: hypertension, NSTI: necrotizing soft tissue infection, SBO: small bowel obstruction, MCC: Motorcycle crash.

1054

	Healthy Subjects	Sepsis Day 4 ± 1	RAP Days 14-21	CCI Days 14-21	p-
	(n=12)	(n=4)	(n=4)	(n=5)	value
Male, # (%)	7 (58)	1 (25)	1 (25)	3 (60)	0.48
Age in years, (μ	46 ± 10	67 ± 22	61 ± 16	58 ± 18	0.08
± SD)					
$BMI~(\mu\pm SD)$		39 ± 19	37 ± 20	21 ± 3	0.19
Septic shock, #		4 (100)	1 (25)	4 (80)	
(%)					
CCI (median)		5.5	2	2	
Comorbidities	Cancer (1), COPD	COPD (1), DM (2),	COPD (1), DM	DM (1), HTN (2)	
(#)	(1), DM (1), HTN	HTN (4)	(1), HTN (4)		
	(3)				
Admission		NSTI (1),	NSTI (2), SBO	Planned operation	
Diagnosis (#)		Choledocholithiasis	(2)	(1), Complication (1),	
		(1), SBO (1), Planned		Intra-abdominal	
		operation (1)		abscess (1)	
				Pancreatitis (1), MCC	
				(1)	

1056Table 2. Percentage of Total MDSCs and MDSC subpopulations from PBMCs via flow1057cytometry. Percentages of total MDSC population in representative septic patients. Blood was1058collected from healthy subjects (n=6), day 4 ± 1 septic patients (n=7), and late sepsis patients at1059days 14-21 (n=3)). PBMCs were isolated and prepared for flow cytometry. Viable cells1060determined followed by gating of CD11b⁺ and CD33⁺ cells. HLA-DR^{low} cells selected to capture1061Total MDSCs. (CD11b⁺ CD33⁺ HLA-DR^{low}) Cells outside the gating of the three MDSC1062subpopulations are classified as "% Ungated."

1063

MDSC Subpopulation	Healthy Subjects	Sepsis Day 4 ± 1	Sepsis Days 14-21
	(n=6)	(n=7)	(n=3)
% Total MDSCs	15.1 (8.1, 16.6)	39.2 (25.2, 55.6)	44.8 (35.6, 56.3)
% E-MDSC	68.1 (49.8, 78.7)	1.4 (0.7, 5.9)	2.3 (2.2, 9.0)
% PMN-MDSC	14.6 (7.4, 36.9)	79.5 (64.4, 89.0)	80.7 (52.0, 85.1)
% M-MDSC	9.2 (4.9, 12.7)	9.1 (8.1, 12.7)	11.5 (9.7, 35.9)
% Ungated	2.0 (1.4, 3.2)	0.7 (0.5, 1.3)	0.7 (0.7, 3.1)

1064

Table 3. Percentage of Total MDSCs and MDSC subpopulations from PBMCs and enriched myeloid cells via flow cytometry. Percentages of total MDSC population in representative septic patients. Peripheral blood mononuclear cells and myeloid cells were collected from the same septic cohorts (n=3 for acute sepsis and n=6 for late sepsis patients) and healthy subjects (n=9). A 3:1 mixture of myeloid cells: enriched PBMCs were prepared for flow cytometry. Cells outside the gating of the three MDSC subpopulations are classified as "% Ungated." Results reported as median (Q1, Q3). E: early, PMN: granulocytic, M: monocytic.

MDSC Subpopulation	Healthy Subjects	Sepsis Day 4±1	Sepsis Days 14-21
	(n=9)	(n=3)	(n=6)
% Total MDSCs	0.3 (0.1, 0.3)	3.1 (1.8, 3.6)	0.8 (0.5, 1.3)
% E-MDSC	1.3 (1.1, 5.3)	0.7 (0.5, 1.2)	1.0 (0.5, 6.0)
% PMN-MDSC	22.9 (11.6, 30.3)	26.7 (16.5, 34.5)	23.5 (16.0, 39.9)
% M-MDSC	67.1 (64.6, 83.1)	71.0 (64.0, 81.4)	68.2 (57.2, 80.6)
% Ungated	0.3 (0.0, 0.5)	0.6 (0.3, 1.6)	0.5 (0.3, 0.7)

1073

Table 4. H-MDSC cell counts by patient and associated outcome after sepsis. H-MDSC cell
 counts as determined by manual annotation. If blood samples were taken from acutely septic
 patients at day 4, then their eventual sepsis classification has been recorded. H: hybrid, CCI:
 chronic critical illness.

Patient #	Patient Classification	Eventual classification if	H-MDSC Cell Counts
		acute sepsis	
1	Acute Sepsis	Early death	0
2	Acute Sepsis	Rapid recovery	0
3	Acute Sepsis	CCI	1

4	Acute Sepsis	CCI	8
5	Rapid recovery		0
6	Rapid recovery		0
7	Rapid recovery		0
8	Rapid recovery		0
9	CCI		552
10	CCI		6
11	CCI		1
12	CCI		0
13	CCI		0

1079 1080

1081

Conflict of Interest 8

The authors declare that the research was conducted in the absence of any commercial or 1082 1083 financial relationships that could be construed as a potential conflict of interest.

1084

9 **Author Contributions** 1085

- 1086
- Conceptualization: MK, CM, LLM, PAE 1087
- Methodology: LLM, PAE 1088
- Investigation: DBD, JCR, MW, MLD, RU, DCN, MLG, SL, LM, TL, AMM, RM, MK, CM, 1089 MAB, TMB, LLM, RB, PAE 1090
- Visualization: LLM, PAE 1091
- 1092 Funding acquisition: MK, CM, LLM, PAE
- Project administration: PAE 1093
- Supervision: PAE 1094
- Writing original draft: ELB, JL, VP, LLM, RB, PAE 1095
- Writing review & editing: ELB, JL, DBD, JCR, MW, VP, GG, JM, MLD, RU, DCN, MLG, 1096 SL, LM, TL, AMM, RM, MK, CM, MAB, TMB, LLM, RB, PAE. 1097
- 1098

1099 10 Funding

- This work was supported, in part, by the following National Institutes of Health grants: 1101
- National Institutes of Health grant RM1 GM139690 (LLM, PAE, MK, CM) 1102
- National Institutes of Health grant R35 GM140806 (PAE) 1103
- National Institute of General Medical Sciences grant R35 GM146895 (RB) 1104
- 1105 National Institute of General Medical Sciences postgraduate training grant T32 GM-008721 (EB,
- DBD, VP, JM) 1106
- National Institute of General Medical Sciences postgraduate training grant T32 HL160491 (GG) 1107
- 1108
- 1109 11 Acknowledgments
- 1110
- The authors would like to thank LaShaun Bryant, BS, Brandi Buscemi, AS Physical Therapist 1111 Assistant, Ruth Davis, BSN, Jennifer Lanz, MSN, RN, Ashley McCray, ASN, and Ivanna Rocha, 1112
- 1113 MPH for their critical role with patient recruitment, retention and data collection as well as
- 1114 collection of human samples.

Data availability

The datasets generated for this study can be found in the Gene Expression Omnibus (in-process).

All analysis codes are available upon request.



UMAP 1

UMAP 1



Day 14-21 (RAP)

Gene Ontology Biological Process





30%

Percent Expressing

40%

50%

10%

.

20%

.

Status	Mean	S.E.
Healthy	88.3%	0.5%
Day 4±1	85.4%	1.3%
Day 14-21 (CCI)	91.3%	0.8%
Day 14-21 (RAP)	88.2%	1.7%

Scaled Mean Expression





medRxiv proprint for the second to the second secon







10 20 30 40





